AnaptysBio (NASDAQ:ANAB) Cut to Sell at StockNews.com

AnaptysBio (NASDAQ:ANABGet Rating) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a report issued on Tuesday.

Other equities analysts have also recently issued reports about the company. Wedbush reiterated a “neutral” rating on shares of AnaptysBio in a research report on Monday, March 14th. HC Wainwright lifted their target price on AnaptysBio from $43.00 to $46.00 and gave the stock a “buy” rating in a report on Monday, March 7th. Zacks Investment Research upgraded AnaptysBio from a “strong sell” rating to a “hold” rating in a report on Thursday, March 17th. Finally, Guggenheim cut AnaptysBio from a “buy” rating to a “neutral” rating in a report on Tuesday, March 22nd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $37.25.

ANAB opened at $23.48 on Tuesday. The firm has a market cap of $649.74 million, a price-to-earnings ratio of -11.18 and a beta of 0.12. AnaptysBio has a fifty-two week low of $21.15 and a fifty-two week high of $37.89. The company’s 50-day moving average price is $26.83 and its 200 day moving average price is $30.33.

AnaptysBio (NASDAQ:ANABGet Rating) last released its quarterly earnings data on Monday, March 7th. The biotechnology company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of $2.28 by ($3.41). AnaptysBio had a negative return on equity of 14.95% and a negative net margin of 91.49%. The business had revenue of $1.01 million for the quarter, compared to analyst estimates of $174.30 million. Equities analysts anticipate that AnaptysBio will post -3.26 EPS for the current year.

Several large investors have recently made changes to their positions in the business. Amundi Pioneer Asset Management Inc. acquired a new position in shares of AnaptysBio during the 1st quarter worth about $110,000. Wells Fargo & Company MN grew its stake in shares of AnaptysBio by 33.7% in the 2nd quarter. Wells Fargo & Company MN now owns 79,701 shares of the biotechnology company’s stock valued at $2,067,000 after purchasing an additional 20,077 shares during the period. Morgan Stanley grew its stake in shares of AnaptysBio by 1.3% in the 2nd quarter. Morgan Stanley now owns 161,675 shares of the biotechnology company’s stock valued at $4,191,000 after purchasing an additional 2,136 shares during the period. WINTON GROUP Ltd bought a new stake in shares of AnaptysBio in the 3rd quarter valued at approximately $312,000. Finally, Los Angeles Capital Management LLC grew its stake in shares of AnaptysBio by 3.5% in the 3rd quarter. Los Angeles Capital Management LLC now owns 130,560 shares of the biotechnology company’s stock valued at $3,541,000 after purchasing an additional 4,355 shares during the period. 99.46% of the stock is owned by institutional investors.

About AnaptysBio (Get Rating)

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.

Featured Stories

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.